Cardurion Pharmaceuticals
Pharmaceutical company developing novel therapies for heart failure and other cardiovascular diseases through strategic partnership with Bayer.
Website
https://www.cardurion.comLocation
Cambridge, Massachusetts, USA
Founded
2016
Categories
biotech, pharmaceuticals, cardiovascular, heart-failure, therapeutics
Notes
Cardurion Pharmaceuticals is a biopharmaceutical company focused on developing novel treatments for heart failure and other serious cardiovascular conditions. The company was founded through a strategic partnership between Bain Capital Life Sciences and Bayer, combining expertise in cardiovascular drug development with significant resources for clinical development.
Cardurion is advancing a pipeline of small molecule therapeutics targeting key pathways involved in heart failure, including PDE9 inhibitors and other novel mechanisms.
Team
- Mark J. Bamberg - Chief Executive Officer
- LinkedIn: linkedin.com/in/markbamberg
- Michael Mendelsohn, M.D. - Chief Medical Officer & Head of R&D
Additional Research Findings
- Founded through Bain Capital Life Sciences and Bayer partnership
- Strategic alliance with Bayer for cardiovascular drug development
- Focus on heart failure therapeutics
- PDE9 inhibitors and novel cardiovascular mechanisms
- Cambridge, Massachusetts headquarters
- Significant pipeline of cardiovascular drugs
- Backed by Bain Capital Life Sciences